ADCETRIS 50mg Infusion/Powder for

What is ADCETRIS 50mg

ADCETRIS 50 mg is a sterile, lyophilized powder for intravenous infusion containing Brentuximab vedotin, an antibody-drug conjugate (ADC) targeting CD30-expressing cells. It's primarily prescribed for adults to treat:

• Classical Hodgkin Lymphoma (cHL): After failure of autologous stem cell transplant or at least two prior multi-agent chemotherapy regimens.
• Systemic Anaplastic Large Cell Lymphoma (sALCL): After failure of at least one prior multi-agent chemotherapy regimen.
• Peripheral T-cell Lymphoma (PTCL): In combination with chemotherapy for previously untreated patients.
• Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) or CD30-expressing Mycosis Fungoides (MF): After prior systemic therapy.

Brentuximab vedotin combines a monoclonal antibody specific for CD30 with the microtubule-disrupting agent monomethyl auristatin E (MMAE), delivering targeted cytotoxicity to malignant cells.

How to use ADCETRIS 50mg

Administration Guidelines:

• Preparation: Reconstitute each 50 mg vial with 10.5 mL of sterile water for injection to yield a 5 mg/mL solution. Further dilute in 100–150 mL of 0.9% sodium chloride or 5% dextrose solution.
• Infusion: Administer as a 30-minute intravenous infusion. Do not administer as an intravenous push or bolus.
• Dosage: Typically, 1.8 mg/kg every 3 weeks. Adjustments may be necessary based on individual patient factors.
• Monitoring: Observe patients during and after infusion for signs of hypersensitivity or infusion-related reactions.

Always follow institutional guidelines and consult the full prescribing information for detailed preparation and administration instructions.

Mode of Action ADCETRIS 50mg

Pharmacodynamics:

• Targeting CD30: The monoclonal antibody component binds specifically to the CD30 antigen on the surface of malignant cells.
• Internalization and Release: Upon binding, the ADC-CD30 complex is internalized, and MMAE is released into the cytoplasm.
• Microtubule Disruption: MMAE binds to tubulin, disrupting the microtubule network, leading to cell cycle arrest and apoptosis.

This targeted approach allows for the selective destruction of CD30-expressing malignant cells while minimizing damage to normal tissues.

ADCETRIS 50mg Interactions ADCETRIS 50mg

Drug Interactions:

• CYP3A4 Inhibitors: Co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole) may increase MMAE exposure, enhancing toxicity. Monitor patients closely.
• CYP3A4 Inducers: Concurrent use with CYP3A4 inducers (e.g., rifampin) may decrease MMAE exposure, potentially reducing efficacy.
• Bleomycin: Concomitant use is contraindicated due to increased risk of pulmonary toxicity.
• Alcohol: May exacerbate hepatotoxic effects; advise patients to limit or avoid alcohol consumption during treatment.

Always review the patient's medication profile for potential interactions before initiating ADCETRIS therapy.

Dosage of ADCETRIS 50mg

Recommended Dosages:

• Monotherapy: 1.8 mg/kg administered as an intravenous infusion over 30 minutes every 3 weeks.
• Combination Therapy: In combination with chemotherapy agents, the dosage may vary. Refer to specific protocols for guidance.
• Dose Adjustments: Modify dosage in patients with hepatic or renal impairment, or in response to adverse reactions such as peripheral neuropathy or hematologic toxicity.

Dosage should be individualized based on patient weight, treatment regimen, and tolerability. Consult the prescribing information for detailed dosing guidelines.

Possible side effects of ADCETRIS 50mg

Common Side Effects:

• Peripheral neuropathy
• Fatigue
• Nausea
• Diarrhea
• Neutropenia
• Upper respiratory tract infection
• Pyrexia
• Constipation
• Vomiting
• Alopecia
• Decreased appetite

Serious Side Effects:

• Progressive multifocal leukoencephalopathy (PML)
• Hepatotoxicity
• Infusion-related reactions
• Stevens-Johnson syndrome
• Tumor lysis syndrome

Patients should be monitored regularly for signs of adverse reactions, and appropriate interventions should be implemented as necessary.

ADCETRIS 50mg Contraindications ADCETRIS 50mg

Contraindicated Conditions:

• Concomitant Bleomycin Use: Due to increased risk of pulmonary toxicity, the combination of ADCETRIS with bleomycin is contraindicated.
• Hypersensitivity: Patients with known hypersensitivity to brentuximab vedotin or any of its components should not receive ADCETRIS.

Assess patient history thoroughly to identify any contraindications before initiating therapy.

Storage of ADCETRIS 50mg

Storage Instructions:

• Unreconstituted Vials: Store at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze.
• Reconstituted Solution: If not used immediately, may be stored at 2°C to 8°C for up to 24 hours. Do not freeze.
• Diluted Infusion Solution: Should be administered immediately. If not used promptly, may be stored at 2°C to 8°C for up to 24 hours. Do not freeze.
• Handling: ADCETRIS is a hazardous drug. Follow appropriate handling and disposal procedures in accordance with institutional guidelines.

Proper storage and handling are essential to maintain the stability and efficacy of ADCETRIS.